Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q4 2020 Earnings Presentation
18 slides from Q-linea Ab's earnings presentation, Feb 18, 2021
Slide 1: Presentation Q4(20)
Presentation Q4(20) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 4th quarter: Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 4th quarter Q-linea is developing disruptive solutions for Lead product ASTar® faster infectious disease diagnostics, first product targeting sepsis Introduction to the company 140 employees & consultants at year end Clin
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis Time to correct treatment critical for patient outcome 4
Slide 5: ASTar workflow vs current workflow
Up to 40 hours faster actionable results And requires minimal hands-on time DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Blood bottle Rapid ID Overnight 0.5
Slide 6: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Easy to use Comprehensive • Fully automated • Large antibiotic panel • <1 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additional • Results in ~6 hours samples (e.g. urine)
Slide 7: ASTar could help save lives
ASTar could help save lives ASTar was much faster than standard AST method and provided a broader answer One example for Uppsala University Hospital pre-clinical study Man 73 years from neuro surgery intermediate care ward, diagnosed with aspiration pneumonia ASTar reported ASTar ”resistant” towards
Slide 8: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide 24-40 hour faster dia
Slide 9: Key highlights fourth quarter
Key highlights fourth quarter Clinical study update European Clinical study started in December The study started according to earlier market communication timelines Preparation for the US clinical study progressed well Reference testing site selection done Selected preferred clinical sites US clini
Slide 10: Key highlights fourth quarter
Key highlights fourth quarter Preparing for launch readiness Commercial instruments inventory build up for launch To enable deliveries to first customers after launch Ramping up consumable production For commercial products, US clinical studies & HEOR studies Marketing message and material Q-linea a
Slide 11: Key highlights fourth quarter
Key highlights fourth quarter Stability study of consumables progress well Shelf life of consumables has now passed 6 months Both consumables perform as expected Goal is to reach 12-month stability during second quarter 2021 Excellent results from transportation studies Important preparation for com
Slide 12: Key highlights fourth quarter
Key highlights fourth quarter Launched development of next generation disruptive technology for blood cultures Has potential to provide equal end better care for all patients • Could save >10 hours for blood culture results • Could enable more streamlined workflow in the lab • Use time instead of wa
Slide 13: Key highlights after period end
Key highlights after period end Clinical study started in December Clinical study progressing well as of today Approximate 2/3 of planned samples analyzed No surprises regarding performance so far CE-IVD certification according to earlier indicated timelines, 3-4 months Assuming no major disruption
Slide 14: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea So far, the effects has not caused a delay on Q-linea operations Most activities coupled to ASTar launch are still internal regarding clinical studies and commercial preparations. Q-linea has seen a slight increase in sickness absence, directly as well a
Slide 15: Income statement fourth quarter
Income statement fourth quarter Net sales in the fourth quarter amounted to SEK 0 million (0). Operating result totalled SEK -57.1 million (-62.1). The company reported a loss after tax of SEK -56.6 million (-62.0). Earnings per share, before and after dilution amounted to SEK -2.10 (-2.71). Figures
Slide 16: Balance sheet at end of year
Balance sheet at end of year Cash and cash equivalents amounted to SEK 10.1 million (26.0) Short-term investments in fixed-income funds SEK 165,7 million (150,4) and the current portion of non-current assets (listed bonds) SEK 131.0 million (30.1). Non-current assets, listed bonds SEK 24.4 million (
Slide 17: Cash flow statement fourth quarter
Cash flow statement fourth quarter Cash flow from operating activities SEK -76.7 million (-52.1). Increased cash outflow from operating activities mainly due to a build up of launch inventories during the quarter and decrease of accounts payables. Cash flow from investing activities SEK 69.1 million
Slide 18: Thank you
Thank you O-LINEA™ 18